The European Medicines Agency is seeking feedback on the use of an artificial intelligence (AI)-based pathology tool that could provide a more reliable assessment of investigational treatments for metabolic dysfunction-associated steatohepatitis (MASH).
Boosting Reliability: EMA Backs AI Tool For MASH Trials
An artificial intelligence-based pathology tool for metabolic dysfunction-associated steatohepatitis shows promise for a drug development landscape that is said to be “fraught with trials that have shown borderline results or outright failures based on liver histology.”
